Metro Healthcare Indonesia (IDX:CARE) - Share price, News & Analysis

CARE fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	4/6
Financial Health	4/6
Dividends	0/6

CARE Stock Overview

PT Metro Healthcare Indonesia Tbk operates and manages hospitals in Indonesia.

Rewards

Earnings grew by 149.2% over the past year

Risk Analysis

High level of non-cash earnings

Metro Healthcare Indonesia Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Metro Healthcare Indonesia
Historical stock prices
Current Share Price	Rp530.00
52 Week High	Rp605.00
52 Week Low	Rp318.00
Beta	-0.22
1 Month Change	1.92%
3 Month Change	-5.36%
1 Year Change	63.58%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	281.29%

Shareholder Returns

	CARE	ID Healthcare	ID Market
7D	-1.9%	1.6%	1.1%
1Y	63.6%	18.5%	18.3%

Return vs Industry: CARE exceeded the ID Healthcare industry which returned 18.5% over the past year.

Return vs Market: CARE exceeded the ID Market which returned 18.3% over the past year.

Price Volatility

Is CARE's price volatile compared to industry and market?
CARE volatility
CARE Average Weekly Movement	4.3%
Healthcare Industry Average Movement	5.7%
Market Average Movement	6.2%
10% most volatile stocks in ID Market	12.0%
10% least volatile stocks in ID Market	2.9%

Stable Share Price: CARE is not significantly more volatile than the rest of ID stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: CARE's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2015	993	Henry Kembaren	https://www.metrohealthcareindonesia.co.id

PT Metro Healthcare Indonesia Tbk operates and manages hospitals in Indonesia. It owns and operates 7 hospitals. The company was founded in 2015 and is based in Tangerang, Indonesia.

Metro Healthcare Indonesia Fundamentals Summary

How do Metro Healthcare Indonesia's earnings and revenue compare to its market cap?
CARE fundamental statistics
Market Cap	Rp17.62t
Earnings (TTM)	Rp21.96b
Revenue (TTM)	Rp289.80b

802.5x

P/E Ratio

60.8x

P/S Ratio

Is CARE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
CARE income statement (TTM)
Revenue	Rp289.80b
Cost of Revenue	Rp141.31b
Gross Profit	Rp148.49b
Other Expenses	Rp126.53b
Earnings	Rp21.96b

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	0.66
Gross Margin	51.24%
Net Profit Margin	7.58%
Debt/Equity Ratio	6.5%

How did CARE perform over the long term?

See historical performance and comparison

Valuation

Is Metro Healthcare Indonesia undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

802.54x

Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CARE's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CARE's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: CARE is poor value based on its Price-To-Earnings Ratio (802.5x) compared to the ID Healthcare industry average (20.1x).

PE vs Market: CARE is poor value based on its Price-To-Earnings Ratio (802.5x) compared to the ID market (18.7x).

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CARE's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: CARE is overvalued based on its Price-To-Book Ratio (5.3x) compared to the ID Healthcare industry average (2x).

Future Growth

How is Metro Healthcare Indonesia forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

16.0%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Metro Healthcare Indonesia has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has Metro Healthcare Indonesia performed over the past 5 years?

Past Performance Score

4/6

Past Performance Score 4/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

35.2%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CARE has a high level of non-cash earnings.

Growing Profit Margin: CARE's current net profit margins (7.6%) are higher than last year (4.4%).

Past Earnings Growth Analysis

Earnings Trend: CARE's earnings have grown significantly by 35.2% per year over the past 5 years.

Accelerating Growth: CARE's earnings growth over the past year (149.2%) exceeds its 5-year average (35.2% per year).

Earnings vs Industry: CARE earnings growth over the past year (149.2%) exceeded the Healthcare industry 121.6%.

Return on Equity

High ROE: CARE's Return on Equity (0.7%) is considered low.

Financial Health

How is Metro Healthcare Indonesia's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Debt Coverage
Interest Coverage

Financial Position Analysis

Short Term Liabilities: CARE's short term assets (IDR641.3B) exceed its short term liabilities (IDR73.4B).

Long Term Liabilities: CARE's short term assets (IDR641.3B) exceed its long term liabilities (IDR196.9B).

Debt to Equity History and Analysis

Debt Level: CARE has more cash than its total debt.

Reducing Debt: Insufficient data to determine if CARE's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: CARE's debt is not well covered by operating cash flow (14.6%).

Interest Coverage: CARE earns more interest than it pays, so coverage of interest payments is not a concern.

Balance Sheet

Dividend

What is Metro Healthcare Indonesia current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate CARE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CARE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CARE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CARE's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CARE has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure

CEO

Henry Kembaren (63 yo)

3.33yrs

Tenure

Mr. Henry Kembaren, MM, is the President Director at PT Metro Healthcare Indonesia Tbk since 2019. He was Financial Analyst at PT Sehat Karunia Utama since 2016 until 2019; President Commissioner of PT Gad...

Leadership Team

Experienced Management: CARE's management team is considered experienced (3.3 years average tenure).

Board Members

Experienced Board: CARE's board of directors are considered experienced (3.3 years average tenure).

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Data	Last Updated (UTC time)
Company Analysis	2022/05/28 00:00
End of Day Share Price	2022/05/27 00:00
Earnings	2021/09/30
Annual Earnings	2020/12/31